Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Precision BioSciences, Inc.NASDAQ: DTIL

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses declines year over year

Q1 FY2026 operating expenses of $19.91M fell 10.1% year over year, ahead of the -13.0% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.3% from the prior quarter. Over 3 fiscal years it compounded at -1.4% a year.

Context

  • Operating expenses amounted to 244.2% of revenue in FY2025, up 106.1 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -10.1% holds above the trailing-twelve-month pace of -13.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.91M-5.3% QoQ
Last fiscal yearDec 2025
$83.66M-11.8% YoY
LTMMar 2026
$82.81M-13.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.1%——
1 year-11.8%——
3-year CAGR-1.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
83.66M USD
Year-over-year change
-11.8%
4-year CAGR
-14.3%

Operating Expenses vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 operating expenses of $82.81M is the 6th highest of the 7 companies compared; the peer median is $116.1M.
  • Its year-over-year change of -13.0% is the 4th highest of 6, against a peer median of -9.5%.
  • Operating expenses amounts to 183.7% of revenue for DTIL, versus a peer median of 421.5%.
DTIL Competitors Peer median
Operating Expenses for DTIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GOSSGossamer Bio, Inc.LTM Mar 2026$234.09M +30.5%-1.2%421.5%
ALECAlector, Inc.LTM Mar 2026$125.25M -17.6%-16.6%680.1%
HRTXHeron Therapeutics, Inc.LTM Mar 2026$117.64M +3.7%-20.1%78.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$114.57M -9.5%+39.9%—
RNAAtrium Therapeutics, Inc.FY2025$95.43M ——512.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026$82.81M -13.0%-1.4%183.7%
QTTBQ32 Bio Inc.LTM Mar 2026$32.06M -49.4%-7.4%59.7%
Peer median (excluding DTIL) $116.1M-9.5%-7.4%421.5%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue115.53M25.1M48.73M68.7M34.26M
Cost of Revenue00002.75M
Gross Profit115.53M25.1M48.73M68.7M31.51M
Gross Margin100.0%100.0%100.0%100.0%92.0%
Research & Development115.24M46.12M53.38M59.56M54.17M
Selling, General & Admin39.67M41.28M39.09M35.3M32.24M
Operating Expenses154.91M87.41M92.46M94.86M83.66M
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
EBITDA(20.27M)(62.79M)(32.04M)13.53M(42.43M)
EBITDA Margin-17.5%-250.2%-65.8%19.7%-123.8%
Operating Income(39.38M)(62.31M)(43.74M)(26.16M)(52.15M)
Operating Margin-34.1%-248.3%-89.8%-38.1%-152.2%
Interest Income208K3.47M7.69M6.76M4.24M
Interest Expense132K1.11M2.23M1.78M1.42M
Other Income / Expenses8.77M(10.6M)1.21M33.33M5.54M
Income Before Tax(30.6M)(72.91M)(42.53M)7.17M(46.61M)
Pre-Tax Margin-26.5%-290.5%-87.3%10.4%-136.0%
Income Tax Expense00000
Net Income(30.6M)(111.64M)(61.32M)7.17M(46.61M)
Net Margin-26.5%-444.8%-125.8%10.4%-136.0%
EPS (Basic)(15.60)(38.10)(15.96)1.05(3.63)
EPS (Diluted)(15.60)(38.10)(15.96)1.04(3.63)
Weighted Avg Shares1.96M2.93M3.84M6.83M12.83M
Weighted Avg Shares (Diluted)1.96M2.93M3.84M6.88M12.83M

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.